In
The News

In The News

Precision Medicine for Obesity: Targeting a Multifactorial Condition
June 5, 2024
Source
Inside Precision Medicine
What’s Next for Obesity Therapeutics? Higher Quality Weight Loss
April 29, 2024
Source
BioSpace
Looking for Attractive Gains in the Weight Loss Space
April 21, 2024
Source
TheStreet Pro
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
April 20, 2024
Source
The Motley Fool
A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug
March 29, 2024
Source
Business Insider
Altimmune boasts of diff erentiated obesity option
March 28, 2024
Source
The Pharma Letter
Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on Obesity and MASH
March 28, 2024
Source
BioSpace
What To Know About Pemvidutide—Altimmune Says Weight Loss Drug Minimized Muscle Mass Loss In Trial
March 27, 2024
Source
Forbes
Altimmune flexes muscle-sparing, adipose tissue-targeted weight loss data
March 27, 2024
Source
FirstWord Pharma
Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart
March 27, 2024
Source
CNBC
Altimmune cuts hepatitis B program, reports more data on its GLP-1/glucagon for obesity and MASH
March 27, 2024
Source
Endpoints
Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial
March 27, 2024
Source
Bloomberg
A Novo Nordisk competitor teased a weight loss drug that minimizes muscle loss seen in other drugs
March 27, 2024
Source
Quartz
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
February 14, 2024
Source
Scrip
Altimmune open to partnerships, deals with drugmakers, says CEO
December 5, 2023
Source
Reuters
What a pair of Phase II obesity results could mean for Altimmune, Pfizer
December 1, 2023
Source
BioCentury
Altimmune’s fate turns around after longer look at obesity trial
December 1, 2023
Source
Endpoints
Altimmune Joins Weight-Loss Race with Phase II Win, Stock Jumps on News
December 1, 2023
Source
BioSpace
Altimmune’s stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss
November 30, 2023
Source
MarketWatch
Altimmune Jumps 66% After Positive Results for Its Obesity Drug
November 30, 2023
Source
Bloomberg
New 'Twincretin' Pemvidutide: Another Option for Obesity
October 16, 2023
Source
Medscape
Biopharmas focus on glucagon, amylin and other targets beyond GLP-1s
October 4, 2023
Source
BioWorld
Development, investments, partnerships climb, but safety is key
October 3, 2023
Source
BioWorld
With high societal costs, a burgeoning market size, developers seek reimbursement for weight-loss meds
October 2, 2023
Source
BioWorld
Merck And Altimmune Vie To Be Leaders In NAFLD And NASH
June 15, 2023
Source
Scrip
Altimmune sees phase 1 success in tricky NASH indication with GLP-1 agonist
September 14, 2022
Source
FierceBiotech
Effects of ALT‑801, a GLP‑1 and glucagon receptor dual agonist, in a translational mouse model of non‑alcoholic steatohepatitis
April 23, 2022
Source
Scientific Reports
Potential New Obesity Drug Heads to Phase II Trials
January 31, 2022
Source
BioSpace
 

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe